The Online Investor
Healthcare M&A image Healthcare M&A » By The Online Investor Staff, updated Fri., Dec. 6, 9:55 PM Recent mergers and acquisitions in the Healthcare M&A category.

Slide #88. Elanco, the animal health division of Eli Lilly and Company Lohmann Animal Health

Acquirer: Elanco, the animal health division of Eli Lilly and Company (NYSE:LLY)
Acquiree: Lohmann Animal Health
Details: Elanco, the animal health division of Eli Lilly and Company (NYSE:LLY), today announced an agreement to acquire Lohmann SE (Lohmann Animal Health), a privately-held company headquartered in Cuxhaven, Germany. Lohmann Animal Health is a global leader in the supply of poultry vaccines and also markets a range of feed additives. The acquisition will establish Elanco as a global poultry leader, solidify Elanco's vaccine presence, broaden Elanco's product offerings and significantly augment Elanco's vaccine manufacturing capabilities.

Eli Lilly and Company is engaged in discovering, developing, manufacturing, and marketing products in two business segments: human pharmaceutical products; and animal health products. Co.'s human pharmaceutical products include: cardiovascular, endocrinology, immunology, neuroscience and oncology products. Co.'s animal health products are comprised of products for animals, among others, which include Clynav™, a vaccine to control pancreas disease in salmon; Coban®, Maxiban®, and Monteban®, anticoccidial agents for use in poultry; as well as products for companion animals, which include Comfortis®, a chewable tablet that kills fleas and prevents flea infestations on dogs.

Eli Lilly SEC Filing Email Alerts Service


Open the LLY Page at The Online Investor »

Company Name: 
Lilly (Eli) & Co
Stock buyback: 
LLY buyback
Website: 
www.lilly.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding LLY: 
95
Total Market Value Held by ETFs: 
$9.19B
Total Market Capitalization: 
$113.94B
% of Market Cap. Held by ETFs: 
8.07%
 

Open the LLY Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes



Strong Buy (3.50 out of 4)
62nd percentile
(ranked higher than approx. 62% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Healthcare M&A - Slide 88 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2019, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.